

CURRICULUM VITAE
04/1/2016

Name: Gary A. Abrams, MD

Work Address: 890 W Faris Rd, Suite 100
Greenville, SC 29605
Phone 864-455-2882
Email- GAbrams@ghs.org

1. Education

1976-1978	A.A.S. (Registered Nurse)	Misericordia School of Nursing, Bronx, NY
1980-1982	B.S. (Physician's Assistant)	Touro College, New York, NY
1986-1990	Doctor of Medicine	Albert Einstein College of Medicine, NY
1990-1992	Post Doctoral Training (Resident)	Yale New Haven Hospital, CT
1992-1995	Post Doctoral Training (Fellowship)	Yale University School of Medicine
	Clinical Research Investigator in Gastroenterology/Hepatology	

Board Certification	Internal Medicine	1994
	Gastroenterology/Hepatology	1995
Re-Certification	Gastroenterology/Hepatology	2005, 2014
Licensure	CT # 032693	1990
	Al #19230	1995
	SC # 37369	2014

2. Faculty Appointments

University of South Carolina-Greenville Medical School

2014-Present Clinical Professor of Medicine

University of Alabama – UAB

2008-2013 Clinical Professor of Medicine
2002-2007 Associate Professor of Medicine
1995-2002 Assistant Professor of Medicine
2002-2007 Fellowship Director, Gastroenterology/Hepatology
2000-2007 Medical Director, Gastroenterology/Hepatology Hospital Service
1999-2007 Scientist, Center for Outcomes and Effectiveness Research and Education
2004-2007 Scientist, Clinical Nutrition Research Center

3. Professional Experience

2014-Present Chief, Gastroenterology/Hepatology Greenville Health System, Greenville, SC
2014-Present Medical Director, GI Endoscopy Unit Greenville Health System, Greenville, SC
2007-2013 Clinical Professor of Medicine, Physician and Managing Director, Alabama Liver and GI Specialists, Baptist Medical Center South, Montgomery, AL
2002-2007 Associate Professor of Medicine, UAB
1995-2002 Assistant Professor of Medicine, UAB
2002-2007 Fellowship Director, Gastroenterology/Hepatology, UAB
1982-1986 Physician Assistant, LIJ Medical Center, New Hyde Park, NY
1979-1980 Registered Nurse, Misericordia Medical Center, Bronx, NY
1978-1979 Registered Nurse, North Central Bronx Hospital, Bronx, NY

4. Membership Professional/Scientific Societies

American Association for the Study of Liver Disease

American Gastroenterological Association
 American Association of Subspecialty Professors
 North American Association for the Study of Obesity

Editorial Position

Editorial Board	World Journal of Gastroenterology Obesity Surgery The Scientific World Journal World Journal of Hepatology
Reviewer	Annals of Internal Medicine Gastroenterology Hepatology Journal of Hepatology Liver Transplantation American Journal of Gastroenterology

5. Grant Support Completed

1. NIH NIDDK R21 "Functional Proteomics of Hepatic Mitochondria in Obesity and Diabetes". PI, Gary A. Abrams with 20% time commitment, Direct Costs \$275,000, 9/15/05 to 9/14/07.
2. NIH NIDDK R21 "Mitochondrial Dysfunction in an Animal Model of NASH". PI Shannon M. Bailey, PhD, Co-investigator: Gary A. Abrams with 5% time commitment, Direct costs \$275,000, 3-1-06 to 2-28-08.
3. Pure-Gar Inc. PI, Gary Abrams, "HPS Garlic Treatment Study". \$415,602 (9/95 to 8/01)
4. UAB CNIR, PI, Gary Abrams, "In-Vivo Muscle Metabolism in Subjects with Hepatopulmonary Syndrome during garlic therapy: Utility of 31-P MRS". \$6,000 (1999)
5. Clinical Nutrition Research Center Pilot/Feasibility Grant. PI: Shannon M. Bailey, PhD, Mentor: Gary A. Abrams "Mitochondrial Dysfunction & NASH" \$25,000 (2004 and 2005)

6. Awards and Honors

2006	Top 10 Teaching Award Department of Medicine
2004	Top 10 Teaching Award Department of Medicine C. Glen Cobbs and Edwin A. Rutsky Award for Clinical Excellence
2003	Top 10 Teaching Award Department of Medicine C. Glen Cobbs and Edwin A. Rutsky Award for Clinical Excellence
2002	Outstanding Teacher Award C. Glen Cobbs and Edwin A. Rutsky Award for Clinical Excellence
2001	Top 10 Teaching Award Department of Medicine C. Glen Cobbs and Edwin A. Rutsky Award for Clinical Excellence
2000	Outstanding Teacher Award
1990	Alpha Omega Alpha, Albert Einstein College of Medicine
1990	Distinction for Research in Gastroenterology Irving M. Ratner Award for Excellence in Pathology
1982	Valedictorian, Touro College
1978	General Excellence Award, Misericordia School of Nursing

7. University Activities/Council and Committees (UAB)

Institutional Review Board
 Clinical Fiscal Council
 LCGME Committee
 Intern Selection Committee
 Clinical Practice Committee

Clinical Advisory Committee
Integrated Medicine Education Subcommittee
Blood Utilization Committee
UAB School of Medicine Academic Recruitment Committee
Utilization Review Committee

8 . Research Experience (Most recent, 2007-2013)

Principal Investigator:

HBV

Sponsor: Bristol-Myers Squibb

Protocol Title: "A Study to Describe the Antiviral Effect of Entecavir (ETV) in Blacks/African Americans and Hispanics with Chronic HBV Infection who are Nucleoside/tide-Naïve"

Protocol # A1463-085

HCV

Sponsor: Bristol-Myers Squibb

Protocol Title: "A Phase 2b Study of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment Naïve Subjects with Chronic Hepatitis C Genotype 1 and 4 Infection"

Protocol # A1444-010

Protocol Title: "A Phase 2B Study of BMS-790052 in Combination with Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Infected Subjects Who are Null or Partial Responders to Prior Treatment with Peginterferon Alfa plus Ribavirin Therapy"

Protocol # A1444-011

Protocol Title: "A Phase 2a/2b Study of BMS-650032 in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment-Naïve Subjects with Genotypes 1 and 4 Chronic Hepatitis C Infection"

Protocol # A1444-014

Protocol Title "A Phase 2a/2b Study of BMS-650032 in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment-Naïve Subjects with Genotypes 1 and 4 Chronic Hepatitis C Infection"

Protocol # A1447-016

Protocol Title: "Open-Label, Single Arm Evaluation of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Black/African-Americans, Latinos, and White/Caucasians with Chronic Hepatitis C Genotype 1 Infection"

Protocol # BMS444-038

Protocol Title: "A Phase 3 Study with Asunaprevir and Daclatasvir (DUAL) for Null or Partial Responders to Peginterferon Alfa and Ribavirin (P/R), Intolerant or Ineligible to P/R Subjects and Treatment Naïve Subjects with Chronic Hepatitis C Genotype 1b Infection"

Protocol # A1447-028

Protocol Title: "A Phase 3 Open-Label Study with Asunaprevir and Daclatasvir Plus Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) (P/R) (QUAD) for subjects Who Are Null or Partial Responders to Peginterferon Alfa 2a Plus Ribavirin with Chronic Hepatitis C Genotypes 1 or 4 Infection"

Protocol #: A1447-029

Protocol Title: “An Open-Label Re-treatment Study with Peg-Interferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Subjects with Chronic Hepatitis C”

Protocol # A1444-026

Protocol Title: “A Long-Term Follow-up Study of Subjects Who Participated in a Clinical Trial in Which BMS-650032 and/or BMS-790052 Was Administered for the Treatment of Chronic Hepatitis C”

Protocol # A1444-046

Protocol Title: “A Phase II, Randomized, Multi-center, Two Part Study of the Safety and Efficacy of Double-blind, Placebo-controlled INX-08189 in Adjunctive Treatment with Peginterferon alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Study Part A, and Open-label INX-08189 in Adjunctive (Interferon Free) Treatment with Daclatasvir and/or Ribavirin (Copegus®) in Study Part B, in Chronically-infected HCV Genotype 2 and 3 Treatment-naïve Subjects”

Protocol # INH-189-003/ BMS A1472-003

Sponsor: Gilead Sciences Inc

Protocol Title: Fission “A Phase 3, Multicenter, Randomized, Active-Controlled Study to Investigate the Safety and Efficacy of PSI-7977 and Ribavirin for 12 Weeks Compared to Pegylated Interferon and Ribavirin for 24 Weeks in Treatment-Naïve Patients with Chronic Genotype 2 or 3 HCV Infection”

Protocol #: P7977-1231

Protocol Title: QUANTUM “An International, Multicenter, Blinded, Randomized Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics following Administration of Regimens Containing PSI-352938, PSI-7977, and Ribavirin in Patients with Chronic HCV Infection”

Protocol #: P2938-0721

Protocol Title: Atomic “ A Multicenter, Open-label, Randomized, Duration Finding Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics following Oral Administration of PSI-7977 in Combination with Pegylated Interferon and Ribavirin in Treatment-Naïve Patients with Chronic HCV Infection Genotype 1, 4, 5, or 6”

Protocol #: P7977-0724

Protocol Title: “A Multi-Center, Placebo-Controlled, Dose Ranging to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Oral Administration of PSI-7977 in Combination with Pegylated Interferon and Ribavirin in Treatment-Naïve Patients With Chronic HCV Infection Genotype 1, and an Open Label Assessment Of PSI-7977 In Patients With HCV Genotypes 2 Or 3”

Protocol # P7977-0422

Sponsor: Roche (formerly Anadys)

CRO: Duke Clinical Research Institute

Protocol Title: “A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of ANA598 Administered with Pegylated Interferon and Ribavirin in Genotype 1 Patients with Chronic Hepatitis C Infection”

Protocol #: ANA598-505

Protocol Title: “Prospective Observational Study on Predictors of Early On-Treatment Response and Sustained Virological Response in a Cohort of Treatment Naïve HCV Infected Patients Treated with Pegylated Interferon”

Protocol # MC21542

Acute Variceal Bleeding/Portal Hypertension**Sponsor: Debiovision, Inc.****Protocol Title:** "The Early Use of Sanvar® with Endoscopic Treatment for the Control of Acute Variceal Bleeding due to Portal Hypertension"**Protocol #:** DEB-VAP/EVB-301**Evaluation of Endoscopy Capsule Device****Sponsor: Given Imaging Ltd.****Protocol Title:** "RD-300: Evaluation of the PillCam® Express Device"**Protocol #** RD-300**Sub-investigator:**

UCB Inc: C87075SECURE "A Non-Interventional Long-term Post-Marketing Registry of Patients Treated with Certolizumab Pegol (Cimzia®) for Crohn's Disease

Abbott: PO6-134 "Adalimumab (HUMIRA®) Clinical Trial Database"

UCB: C87065 "An open-label, multi-center trial to examine the long term safety, efficacy, and corticosteroid-sparing effect of certolizumab pegol in patients with moderate to severe Crohn's disease who have failed tapering of corticosteroids, needed corticosteroids after completion of tapering, or have successfully completed the trial C87059 (COSPAR I)" (COSPAR II)

UCB: C87059 "A Phase IIIb, multi-center, double-blind, placebo-controlled, randomized trial to examine the corticosteroid-sparing effect of Certolizumab pegol in patients with moderate to severe Crohn's disease" (COSPAR I)

United BioSource/ Elan: ELN100226-CD451CD INFORM database study

Prometheus: 08CP01 "A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of COLAL-PRED® in the Treatment of Patients with Moderate to Severe Ulcerative Colitis"

- 1993-1995 Training Program in Clinical Investigation Supported by the NIDDK
- 1989 Senior 6 month project in Biochemistry and Gastroenterology, supervised Dr. Irving Listowsky, Albert Einstein College of Medicine
- 1987 Neuropathology Research Trainee, supervised by Dr. William Lyman, Albert Einstein College of Medicine (1 year)

9. Teaching Experience

University of Alabama at Birmingham

Introduction to Clinical Medicine Course, 1997, 1999, 2001 and 2002

Clinical Hepatology and Liver Transplantation Course, UAB Liver Center, 1997

Evaluation of Hypoxemia in Cirrhotic Patients

Advances in Clinical Hepatology and Liver Transplantation, UAB Liver Center, 1999

Nonalcoholic Steatohepatitis

Moderator, Case Discussions – Hepatitis

University of Alabama at Birmingham

7th Annual Internal Medicine Board Review Course, Hepatology Review, 2000

New Approaches to Evaluation and Treatment of Liver Disease, UAB Liver Center, 2001

Appropriate Uses of Commonly Prescribed Drugs in Liver

Moderator, Gastroenterology/Hepatology Grand Rounds 2002, 2003, 2004, 2005, 2006

Medical Student GI/Hepatology Pathophysiology Course

Lecture: Hepatic Steatosis – Alcoholic and Nonalcoholic Fatty Liver Diseases 2004, 2005, 2006

Baptist Medical Center South- teaching medical residents during monthly GI/Hepatology ward rotations
2007-present

Publications (peer-reviewed)

1. **Abrams GA**, Jaffe CC, Hoffer PB, Binder HJ and Fallon MB. Diagnostic Utility of Contrast Echocardiography and Lung Perfusion Scan in Hepatopulmonary Syndrome. Gastroenterology 1995; 109:1283-1288.
2. **Abrams GA**, Concato J and Fallon MB. Prevalence of Muscle Cramps in Patients With Cirrhosis. Am J of Gastro 1996; 91:1363-1366.
3. Fallon MB, **Abrams GA**, Luo B, Hou Z, Dai J and Ku DD. The Role of Endothelial Nitric Oxide Synthase in the Pathogenesis of a Rat Model of Hepatopulmonary Syndrome. Gastroenterology 1997; 113:606-614.
4. Fallon MB, **Abrams GA**, Hou Z and Luo B. Common bile duct ligation in the rat: A model of intrapulmonary vasodilatation and the hepatopulmonary syndrome. Am J Physiol 1997; 272:G779-G784.
5. Raymond RS, Fallon MB and **Abrams GA**. Ineffectiveness of a Dietary Supplement Containing Thymic Extract in Chronic Hepatitis C. Annals of Internal Med 1998; 129:797-800.
6. Luo B, **Abrams GA**, and Fallon MB. Endothelin-1 in the rat bile duct ligation model of hepatopulmonary syndrome: Correlation with pulmonary dysfunction. J of Hepatology 1998; 29:571-8.
7. **Abrams GA** and Fallon MB. Treatment of Hepatopulmonary Syndrome With Allium Sativum L. (Garlic): A Pilot Trial. J of Clin Gastroenterol 1998; 27:232-35.
8. Fallon MB, Abrams GA, Abdel-Razek TT, Dai J, Chen, SJ, Chen YF, Luo B, Oparil S and Ku DD. Garlic Prevents Hypoxic Pulmonary Hypertension in Rats. Am J of Physiol 1998; 275:L283-287.
9. **Abrams GA**, Nanda NC, Dubovsky EV, Krowka MJ, and Fallon MB. Use of Macroaggregated Albumin Lung Perfusion Scan to Diagnose Hepatopulmonary Syndrome: A New Approach. Gastroenterology 1998; 114:1-6.
10. Thakur AC, Nanda NC, Malhotra S, St.Martin MB, Jamie F, Agrawal D, Maheshwari S, **Abrams GA**, and Patel B. Combined Interatrial and Intrapulmonary Shunting in Orthodeoxia Detected by Transesophageal Echocardiography. Echocardiography 1998; 15:101-104.
11. **Abrams GA**, Rose K, Fallon MB, McGuire BM, Bloomer JR, van Leeuwen DJ, Tutton T, Sellers MT, Eckhoff DE, Bynon JS. Hepatopulmonary Syndrome and Venous Emboli Causing Intracerebral Hemorrhages after Liver Transplantation: A Case Report. Transplantation 1999; 68:1809-11.
12. Zhang M, Luo B, Chen SJ, **Abrams GA** and Fallon MB. Endothelin-1 stimulation of endothelial nitric oxide synthase in the pathogenesis of hepatopulmonary syndrome. Am J of Physiol 1999; 227, G944-952.
13. Fallon MB, **Abrams GA**. Hepatopulmonary Syndrome. Curr Gastroenterol Rep 2000;2:40-45.
14. Fallon MB, **Abrams GA**. Pulmonary dysfunction in chronic liver disease. Hepatology 2000;32:859-65
15. Arguedas MR, McGuire BM, Fallon MB, **Abrams GA**. The use of screening and preventive therapies for gastroesophageal varices in patients referred for evaluation of orthotopic liver transplantation. Am J Gastroenterol. 2001; 96 (3): 833-7.
16. Liu L, Zhang M, Luo B, **Abrams GA**, Fallon MB. Biliary Cyst Fluid from Common Bile Duct Ligated Rats Stimulates Endothelial Nitric Oxide Synthase in Pulmonary Artery Endothelial Cells: A Potential Role in Hepatopulmonary Syndrome. Hepatology 2001; 33:722-27.
17. Arguedas MR. Heudebert GR. Eloubeidi MA. **Abrams GA**. Fallon MB. Cost-effectiveness of screening, surveillance, and primary prophylaxis strategies for esophageal varices. American Journal of Gastroenterology. 2002; 97(9):2441-52.
18. **Abrams GA**, Sanders MK, Fallon MB. Utility of Pulse Oximetry in the Detection of Arterial Hypoxemia in Liver Transplant Candidates. Liver Transplantation 2002; 8:391-396.
19. Ku DD, Abdel-Razek TT, Dai J, SangAe Kim-Park, Fallon MB and **Abrams GA**. Garlic and Its Active Metabolite, Allicin, Produce Endothelium and Nitric Oxide dependent Relaxation in Rat Pulmonary Arteries. Clin Exp Pharmacology and Physiology 2002; 29:84-91.
20. Arguedas MR, **Abrams GA**, Krowka MJ, Fallon, M.B. Prospective Evaluation of Outcomes and Predictors of Mortality in Patients with Hepatopulmonary Syndrome Undergoing Liver Transplantation. Hepatology 2003; 37:192-7.

21. Hicken BL, Sharara AI, **Abrams GA**, Eloubeidi M, Fallon MB, Arguedas MR. Hepatic venous pressure gradient measurements to assess response to primary prophylaxis in patients with cirrhosis: a decision analytical study. Alimentary Pharmacology & Therapeutics. 2003; 17(1):145-53.
22. **Abrams GA**, Kunde SK, Lazenby AJ, Clements RH. Portal Fibrosis and Hepatic Steatosis in Morbidly Obese Subjects: A Spectrum of Nonalcoholic Fatty Liver Disease. Hepatology. 2004; 40(2): 475-483.
23. Kunde SK, Lazenby AJ, Clements RH and **Abrams GA**. Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. Hepatology 2005; 42:650-656.
24. Covelli C, Liu X, Jhala N, **Abrams GA**. Advanced Liver Disease associated with the rare Alpha 1-antitrypsin phenotype IZ. Gastroenterology and Hepatology 2006; 2:1-3.
25. Arun J, Leeth T, Lazenby AJ, Clements RH, **Abrams GA**. The Prevalence of Nonalcoholic Steatohepatitis is Greater in Men Compared to Women Undergoing Bariatric Surgery. Obesity Surgery 2006; 16:1-5.
26. Arun J, Liu, X, Jhala N, Lazenby AJ, Clements RH, **Abrams GA**. Influence of Liver Biopsy Heterogeneity in Diagnosing Nonalcoholic Steatohepatitis in Subjects Undergoing Gastric Bypass Surgery. (Obesity Surgery, 2007:17; 155-61)
27. Liu X, Lazenby AJ, Arun J, Leeth T, Clements RH, **Abrams GA**. Steatosis and Hepatocellular Injury Resolve after Gastric Bypass Surgery (Obesity Surgery, 2007:17; 486-92).
28. Qureshi K, Clements RH, **Abrams GA**. The Utility of the "NAFLD fibrosis score" in morbidly obese subjects with NAFLD. Obesity Surgery, 2008:18(3):264-70.
29. Boetticher NC, Peine CJ, Kwo P, **Abrams GA**, Patel T, Aqel B, Boardman L, Gores GJ, Harmsen WS, McClain CJ, Kamath PS, Shah VH. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology. 2008 Dec;135(6):1953-60.
30. Yang YK, Chen M, Clements RH, **Abrams GA**, Aprahamian CJ, Harmon CM. Human mesenteric adipose tissue plays unique role versus subcutaneous and omental fat in obesity related diabetes. Cell Physiol Biochem. 2008;22(5-6):531-8. Epub 2008 Dec 9.
31. Mantena SK, Vaughn Jr DP, Andringa KK, Eccleston H, King AL, **Abrams GA**, Nagy TR, Doeller J, Kraus D, Victor Darley-Usmar V and Shannon M. Bailey. High Fat Diet Induces Hepatic Hypoxia and Enhances Nitric Oxide-Dependent Inhibition of Mitochondrial Respiration. Biochem J. 2009 Jan 1;417(1):183-93.
32. Qureshi K, Saeed F, Clements RH, **Abrams GA**. Comparative Evaluation of Whole Body and Hepatic Insulin Resistance Using Indices from Oral Glucose Tolerance Test in Morbidly Obese Subjects with Nonalcoholic Fatty Liver Disease. J of Obesity. 2010, Article ID 741521, 7 pages doi:10.1155/2010/741521.
33. Eccleston HB, Andringa KK, King AL, Mantena SK, Tinsley HN, Nolte RN, Nagy TM, **Abrams GA**, and Shannon M. Bailey. Chronic Exposure to a High-Fat Diet Induces Hepatic Steatosis, Impairs Nitric Oxide Bioavailability, and Modifies the Mitochondrial Proteome in Mice. Antioxid Redox Signal 2011;15:447-59.
34. Pol S, Ghalib R, Rustgi V, et al A randomised, placebo-controlled trial of daclatasvir (BMS-790052), a first-in-class NS5A replication complex inhibitor, for previously untreated chronic hepatitis C genotype 1 infection. Lancet Infect Dis. 2012;12:671-7.
35. Atiq O, Khan AS, **Abrams GA**. Metastatic Amelanotic Melanoma of Jejunum diagnosed on capsule endoscopy; a case report and review of literature. Gastroenterology and Hepatology. 2012; 8; 691-3
36. Bronowicki J-P, Pol S, Thuluvath P et al Randomized Study of Asunaprevir plus Peginterferon and Ribavirin for Previously Untreated Genotype 1 Chronic Hepatitis C. Antivir Ther. 2013 (Epub ahead of print).
37. Lawitz E, Lalezari JP, Hassanein T et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naïve patients with genotypes 1, 2, and 3 hepatitis C infection: a randomized, double-blind, phase 2 trial. Lancet Infect Dis. 2013;13:401-8.
38. Atiq O, **Abrams GA**. An Uncommon Complication of Peptic Ulcer Disease. Gastroenterol Hepatol 2014 May;10(5):333-4

39. Rasheed K, Arora S, Patel RV et al. Place of Liver Transplant in Alcoholic Hepatitis. *J Gastrointestinal Dig Syst.* 2015;5:334. doi:10.4172/2161-069X/1000334
40. Qureshi K, **Abrams GA**. Prevalence of Biopsy Proven Nonalcoholic Fatty Liver Disease and in Severely Obese Subjects without Metabolic Syndrome. *Clin Obes.* 2016 Apr;6(2):117-23. doi: 10.1111/cob.12132. Epub 2016 Feb 8.
41. Jamal H, **Abrams G**. A corny cause of cerebrospinal fluid ascites: A case report and review of literature. *SAGE Open Med Case Rep.* 2016 Jul28;4:2050313X16661961.

Reviews

1. Fallon MB and Abrams GA. Cardiopulmonary Forum: Hepatopulmonary Syndrome. *Liver Transplantation and Surgery.* 1996; 2:313-319.
2. Abrams GA and Fallon MB. The Hepatopulmonary Syndrome. *Clinics in Liver Disease.* 1997; 1:185-200.
3. Fallon MB and Abrams GA. The Hepatopulmonary Syndrome. *Progress in Liver Disease.* 1997; 247-264.
4. Fallon MB and Abrams GA. Pulmonary Dysfunction in Liver Disease. *Hepatology* 2000; 32:859-865.
5. Fallon MB and Abrams GA. Hepatopulmonary Syndrome. *Current Gastroenterology Reports.* 2000; 2:4-46.
6. Abrams GA and Qureshi K. Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of Nonalcoholic Fatty Liver Disease. (*World Journal of Gastroenterology* 2007;14; 3540-53).

Book Chapters

1. Abrams GA and Fallon MB. Diseases of the Liver and Biliary system, Chapters 39 - 45. In: *Cecil's Essentials of Medicine.* C. Bennett and T. Andreoli eds. 3rd edition, Saunders, Philadelphia, PA, (1997).
2. Abrams GA, Fallon MB, Gomez CR, Nanda NC. Detection of Intrapulmonary Vasodilatation and Diagnosis of Hepatopulmonary Syndrome With Contrast Echocardiography. *Advances in Echo Imaging Using Contrast Enhancement.* 2nd Ed., 265-275, Kluwer Academic Pub. Dordrecht/Boston/London, Nanda NC and Schlieff R. and Goldberg BB (editors). 1997
3. Abrams GA. Diseases of the Liver and Biliary system, In: *Cecil's Essentials of Medicine.* C. Bennett and T. Andreoli eds. 5th edition, Saunders, Philadelphia, PA, (2001).
4. Fallon MB and Abrams GA. Cardiovascular and Pulmonary Complications in Patients with Liver Disease. Chapter 18. In: *Hepatology: A Textbook of Liver Disease.* Zakim and Boyer eds. 4th edition (2003).
5. Abrams, GA. MKSAP-13 Gastroenterology and Hepatology Self-Assessment Program, American College of Physicians (2003).
6. Abrams GA. Diseases of the Liver and Biliary system, In: *Cecil's Essentials of Medicine.* T. Andreoli eds. 6th edition, Saunders, Philadelphia, PA, (2004).

Abstracts and Presentation

1. Abrams GA, Lyman WD and Raine CS. Experimental Autoimmune Encephalomyelitis: Isolation And Characterization Of Inflammatory Cells In The Central Nervous System. Oral presentation at the National Student Research Forum, Texas, 1988.
2. Abrams GA, Manzione N, Takahashi Y, Chowdhury Roy N, Chowdhury Roy J, and Listowsky I. Glutathione-S-Transferase Is A Tissue Marker For Colonic Polyps With Malignant Potential: *Gastroenterology* 1990. Second place award oral presentation at the Digestive Disease Annual Scientific Sessions, Texas.
3. Abrams GA, Krowka MJ, Crapo RO, Fallon MB. Hepatopulmonary Syndrome: Open label trial with allium sativum (garlic). *Hepatology* 1995;22:167A. AASLD Annual Meeting Poster Presentation
4. Fallon MB, Abrams GA, Chen YF, Oparil S, Garcia-Cardena G, Sessa WC and McGrath JW. Altered pulmonary expression of vasoactive mediators in a rat model of hepatopulmonary syndrome. *Hepatology* 1995;22: 921A. Oral presentation, Plenary session, American Association for the Study of Liver Diseases annual meeting, Chicago, IL.

5. Abrams GA, Erbas B, Krowka MJ, Fallon MB. An Abnormal Lung Perfusion Scan Is Specific For The Hepatopulmonary Syndrome in Hypoxemic Cirrhotics. *Hepatology* 1996. AASLD Annual Meeting Poster Presentation.
6. Fallon MB, Abrams GA, Hou Z, Luo B and Ku DD. Role of Endothelial Nitric Oxide Synthase (eNOS) in the Pathogenesis of a Rat Model of Hepatopulmonary Syndrome. *Hepatology* 1996. AASLD Annual Meeting Poster Presentation.
7. Fallon MB, Abrams GA, Hou Z, and Luo B. Intrapulmonary vasodilatation occurs in a rat model of hepatopulmonary syndrome. *Gastroenterology* 110: A1188, 1996. Oral presentation American Gastroenterological Association annual meeting, San Francisco, CA.
8. Abrams GA, Fallon MB, Nanda NC, Echhoff DE, Bynon JS Jr. Utility of Pulmonary Function Tests, Arterial Blood Gas and Echocardiography in the Pre-Operative Evaluation for Liver Transplantation. *Hepatology* 1997. AASLD Annual Meeting Poster Presentation.
9. Ku DD, Abdel-Razek TT, Dai J, Fallon MB and Abrams GA. Mechanisms of Garlic -Induced Pulmonary Vasorelaxation: Role of Allicin. *Circulation* 1997;96:1-6 (Oral Presentation).
10. Luo B, Abrams GA, and Fallon MB. Endothelin-1: A Potential Endocrine Mediator of Intrapulmonary Vasodilatation in a Rat Model of Hepatopulmonary Syndrome. *Hepatology* 1997, AASLD Annual Meeting Poster Presentation.
11. Fallon MB, Abrams GA, Luo B, Hou Z, Chen YF, and Oparil S. Altered Organ Levels of Vasoactive Mediators in Cirrhotic and Non-Cirrhotic Rat Models of Portal Hypertension. *Gastroenterology* 1997. DDW Annual Meeting Oral Presentation.
12. Abdel-Razek TT, Dai J, Fallon MB, Abrams GA and Ku DD. Role of Endothelium and Nitric Oxide Synthesis on Garlic Extract Induced Vasorelaxation. *FASEB* 11:A81, 1997, Annual Meeting Poster Presentation.
13. Sood G, Fallon MB, Niwas S, Tutton T, van Leeuwen DJ, Bloomer JR, McGuire BM, Sellers MT, Eckhoff DE, Bynon JS, Abrams GA. Utility of A Dyspnea-Fatigue Index For Screening Liver Transplant Candidates For Hepatopulmonary Syndrome. *Hepatology* 1998. AASLD Annual Meeting.
14. Zang M, Luo B, Abrams GA, Fallon MB. Endothelin Stimulates Endothelial Nitric Oxide Synthase Production in Pulmonary Endothelium: A Model of Pathogenetic Mechanism in a Rat Model of Hepatopulmonary Syndrome. *Hepatology* 1998. AASLD Annual Meeting Oral Presentation.
15. van Leeuwen DJ, Langner R, Fallon MB, Abrams GA, Bloomer JR, Crowe R, McGuire BM. Hepatitis C 1998: Prevalence in a Hepatology Referral Practice and Potential For Viral Eradication. *Hepatology* 1998. AASLD Annual Meeting Poster Presentation.
16. van Leeuwen DJ, Langner R, Abrams GA, Bloomer JR, Crowe R, and Fallon MB. Initial Experiences With Interferon and Ribavirin for Hepatitis C: Tolerability of Treatment in an Academic Center. *Hepatology* 1998. AASLD Annual Meeting.
17. Ku DD, Abdel-Razek TT, Kim-Park SA, Fallon MB and Abrams GA. Garlic Extract Modulation of Human Coronary Vascular Tone: Comparisons Between Near Normal and Atherosclerotic Arteries. Second International Congress on Coronary Artery Disease-From Prevention to Intervention 1998.
18. Ku DD, Abdel-Razek TT, Dai J, Fallon MB and Abrams GA. Garlic Extract Modulation of Pulmonary Vascular Function: Comparisons Among Fresh, Aged, Freeze-Dried Powder and Oil Macerate. *FASEB* 1998.
19. Abrams GA, Fallon MB, Nail C, McGuire BM, van Leeuwen DJ, Eckhoff DE, Bynon JS, Bloomer JR. Pulse Oximetry: Utility In Detecting Arterial Hypoxemia I Subjects With Cirrhosis. *Hepatology*, 1999. AASLD Annual Meeting.
20. Abrams GA, Fallon MB, Langner R, Leland LJ, Bloomer JR, McGuire BM, Fallon HJ, van Leeuwen DJ. Delayed HCV-RNA Response During Interferon-Ribavirin Treatment: Effects of Genotype and Viral Titer at Week 12. *Hepatology*, 1999. AASLD Annual Meeting.
21. Arguedas MR, McGuire BM, Fallon MB, Abrams GA. Adherence to vaccination guidelines in patients with chronic liver disease. *Hepatology*, 2000. AASLD Annual Meeting.

22. Johnson A, Abrams GA, Fallon MB, Langner RG, van Leeuwen DJ, McGuire BM, Bloomer JR. Thyroid abnormalities in patients with chronic hepatitis C treated with interferon-alpha and ribavirin. *Hepatology*, 2000. AASLD Annual Meeting.
23. Abrams GA, Krowka MJ, Fallon MB. Prospective evaluation of outcomes and predictors of mortality in patients undergoing liver transplantation for hepatopulmonary syndrome. *Hepatology*, 2001. AASLD Annual Meeting.
24. Liu LC, Luo B, Wang ZS, Abrams GA, Fallon MB. Endothelin-1 stimulates eNOS expression and activity in rat pulmonary microvascular endothelial cells. *Hepatology*, 2001. AASLD Annual Meeting.
25. Abrams GA, Johnson VA, Nail CD, Jhala NC, Fallon MB, McGuire BM, Bloomer JR, Arguedas M, van Leeuwen DJ. Quantification of hepatitis C virus RNA levels in plasma, peripheral blood mononuclear cells (PBMC) and liver tissue. *Hepatology*, 2001. AASLD Annual Meeting.
26. Wang ZS, Luo B, Sun JZ, Abrams GA, Fallon MB. Transforming growth factor beta 1 stimulates endothelin-1 expression in rat cholangiocytes. *Hepatology*, 2001. AASLD Annual Meeting.
27. Hicken B, Arguedas MR, Abrams GA, Fallon MB. Should we routinely measure HVPG to assess response of primary prophylaxis in patients with cirrhosis? A decision analytic study. *Hepatology*, 2001. AASLD Annual Meeting.
28. Reddy N, Abrams GA, Kunde SS, Lazenby A, Jhala N, Bloomer JR. The Prevalence of Antinuclear Antibody in Patients with Nonalcoholic Fatty Liver. *Gastro*, 2003. American Gastroenterological Association Annual Meeting.
29. Sachin K, Abrams GA, Clements RH, Lazenby A, Leath T. Associated of Nonalcoholic Steatohepatitis and Metabolic Syndrome in Morbidly Obese Subjects. NAASO 2003, Oral Presentation.
30. Abrams GA, Jhala N, Lazenby AJ, Kunde S, Leath T, Clements RH. Comparison of Paired Liver Biopsies in Morbidly Obese Subjects with Nonalcoholic Fatty Liver Disease. DDW 2004 Poster Presentation
31. Chen M, Yang Y, Georgeson K, Abrams GA, Clements R, Harmon CM. The Role of Ghrelin in the Regulation of CD36 expression in the Adipose Tissue of Human Obese Patients. Nutrition Week 2004
32. Meleth S, Zhu L, Oeschlager D, Chhieng D, Abrams GA, Piyathilake C, Grizzle WE. Using AUC instead of peaks to compare SELDI TOF spectra. IBC/ASC 2004, Oral Presentation.
33. Abrams GA, Kunde S, Sanders P, Clements RH. Association of Adipose Tissue TGF- β 1 with Hepatic Fibrosis in Morbidly Obese Subjects. AASLD 2004 poster presentation.
34. Kunde S, Sanders P, Clements RH, Abrams GA. Adipose Tissue Content of Transforming Growth Factor-Beta Is Associated With Hepatic Fibrosis In Morbidly Obese Subjects With Nonalcoholic Fatty Liver Disease. NAASO 2004 poster presentation.
35. Akdamar M, Lockart M, Berland L, Abrams GA. Computed Tomography Screening for Hepatocellular Carcinoma: What is the Significance of Indeterminate Lesions? DDW 2005 poster presentation.
36. Kunde S, Clements RH, Abrams GA. The Spectrum of Nonalcoholic Fatty Liver Disease Utilizing the Updated Limits of Normal Serum Aminotransferase Levels. DDW 2005 poster presentation.
37. Settles D, Harding S, Arun J, Clements RH, Abrams GA. Obstructive Sleep Apnea in Morbidly Obese Patients: Does Severity Correlate With Nonalcoholic Steatohepatitis? DDW 2006 poster presentation.
38. Yarbrough D, Clements RH, Leath T, Lazenby A, Abrams GA. Significantly Abnormal Liver Histology Accompanies Morbid Obesity in Individuals Undergoing Laparoscopic Roux-en-Y Gastric Bypass. ASBS 2006 Poster presentation – Top Poster Award.
39. Johnson MS, Zaragosa C, Darley-Usmar V, Abrams GA, Landar A. A proteomic analysis of human liver mitochondria during NASH. Oxidative Post-translation in Cardiovascular Disease. 2006
40. Liu X, Abrams GA, Clements R, Jhala N, Lazenby AJ. Improvement of Nonalcoholic Fatty Liver Disease after Laparoscopic Roux-en-Y Gastric Bypass Surgery for Morbid Obesity. UCAP 2007.
41. Pol S, Ghalib RH, Rustig VK et al. First Report of SVR 12 for a NS5A Replication Complex Inhibitor, BMS 790052, in Combination with PEG-Intron A and RBV Phase II a Trial in Treatment Naive HCV Genotype 1. EASL 2011.
42. Bronowicki J, Pol S, Thuluvath P et al. BMS 650032, an NS3 Inhibitor, In Combination with PEG-Intron 2a and Ribavirin in Treatment Naïve Subjects with Genotype 1 Chronic HCV Infection. EASL 2011.

43. Nelson DR, Lalezari J, Lawitz E et al. PSI 7977 QD Plus PEG/RIBA in HCV GT1: 98% Rapid Virologic Response, Complete Early Viral Rapid Response: The PROTON Study. EASL 2011.

Invited Presentations

1. West Expo Alternative Medicine-1998, Garlic's Effect on Pulmonary Vascular Tone.
2. Early Morning Workshop, AASLD Annual Meeting 1999. Hepatopulmonary Syndrome.
3. Early Morning Workshop, AASLD Annual Meeting 2000. Hepatopulmonary Syndrome.
4. International Garlic Symposium-2000, American Herbal Products Association. Treatment of Hepatopulmonary Syndrome with Garlic.
5. Alabama Chief Resident Medical Society, 13th Annual Meeting, 2001, Utilization of Pulse Oximetry in Subjects with Cirrhosis.
6. Medical Grand Rounds- Nonalcoholic Fatty Liver Disease: Daytona, FL. 2005
7. Medical Grand Rounds- Update on Nonalcoholic Fatty Liver Disease: Montgomery AL 2006.
8. Update on Nonalcoholic Fatty Liver Disease: CME Wetumpka, AL 8/2007
9. Update on Nonalcoholic Fatty Liver Disease: CME UAB Liver Meeting; Birmingham, AL 9/2007
10. Update on Nonalcoholic Fatty Liver Disease: CME Troy, AL 10/2007.
11. ACP Annual Meeting - Update on Nonalcoholic Fatty Liver Disease, Perdido, FL 2008.